Sage Therapeutics

SAGE

Market cap $545M

Sage (SAGE) Q2 Revenue Jumps 264%

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $1.7 per share a year ago.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. “Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “As we work with.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon.

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Sage Therapeutics, Inc. (NASDAQ:  SAGE ) related to its sale to Supernus Pharmaceuticals, Inc. Upon completion of the proposed transaction, current Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable (i) $0.50 the first commercial sale of the drug Zurzuvae in Japan to third-aprty consumers following regulatory approval on or before June 30, 2026; (ii) $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. on or before December 31, 2028; and (iii) $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. on or before December 31, 2030. Is it a fair deal?

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon.

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.